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Both myostatin (MSTN) and activin A, two peptide 
members of the transforming growth factor (TGF)-β su-
per family, have been suggested to play major roles in 
complications of chronic kidney disease (CKD), includ-
ing vascular and bone disease. Both MSTN and activin 
A share many similarities in terms of structure, signaling 
pathway, and functions with TGF-β, and have been ini-
tially studied as players in muscle cachexia in CKD and 
several other chronic diseases [1]. However, the last few 
years have witnessed a paradigm shift with respect to our 
understanding of the effects of MSTN/activin signaling in 
organs distant from muscle. There is ever-increasing evi-
dence that the MSTN/activin pathway impacts the heart, 
arterial vessels, insulin sensitivity and vascular remodel-
ing [2]. In addition, recent observations strongly suggest 
that activin A signaling plays a major role in the progres-
sion of kidney disease and CKD/mineral bone disorder 
(MBD) [2]. These “off target” actions of MSTN and activin 
A might contribute substantially to the pathophysiology 
of wasting, inflammation, vascular damage, and possibly 
progressive renal dysfunction in CKD. 
Like other members of the TGF-β family, MSTN is syn-
thesized as a precursor protein made up of two protein 
domains, an NH2-terminal pro-peptide and a mature 
COOH-terminus domain, which after cleavage, give rise 
to a 26-kDa active processed peptide [1,2]. Of special 
interest is the fact that in muscle, activin A and MSTN 
bind to the same surface receptor complex and activate 
the same signaling cascade that leads to Smad2/3 trans-
location into the nucleus (Fig. 1). Binding of MSTN and 
activin to the ActRIIB and ActRIIA receptor complexes, 
respectively, on cell membranes leads to activation of 
Smad2/3-mediated transcription, which in turn stimu-
lates protein breakdown, inhibits protein synthesis by 
suppressing Akt signaling, and promotes tissue fibrosis 
[1]. MSTN binds with a weaker affinity to the ActRIIA re-
ceptor than to the ActRIIB receptor. The activities of both 
MSTN and activin A are regulated by their latent com-
plexes, where propeptide remains associated and pre-
vents binding to the receptor, and also by follistatin (FSTL) 
and FSTL-like proteins, which inhibit activity. Several 
activities of other members of the TGF-β family, such as 
growth differentiation factor (GDF) 11, are redundant 
with those of MSTN and Activin. 
ActRIIA/B receptor activation in nonclassical tissues, 
such as smooth muscle cells, inflammatory cells, and 
bone may have deleterious effects on organ structure and 
function (Fig. 1). Besides its actions on protein catabo-
lism, MSTN exerts many effects on glucose metabolism 
and might participate in the pathophysiology of athero-
sclerosis. MSTN deficiency protects against insulin re-
sistance and atherosclerosis [2]. In human aortic athero-
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sclerosis, MSTN is upregulated in the media, neointima, 
and cells infiltrating the vessel wall, where it plays an 
active role in monocyte chemiotaxis and ultimately in hin-
dering vascular wall remodeling [3]. The effects of MSTN 
on bone are less well-studied. Studies of MSTN-knockout 
mice revealed that early bone regeneration and inhibition 
of MSTN leads to an increase of osteogenesis. Myo-/- mice 
showed increases in density, strength, and bone mineral-
ization. In clinical studies, inhibition of MSTN has been 
shown to increase the osteogenic potential and bone min-
eralization in patients with diabetes mellitus [4]. 
Activin A signaling appears to be more involved than 
MSTN signaling in CKD-MBD and vascular calcifica-
tion. Activation of the ActRIIA receptors can increase 
vascular smooth muscle cell (VSMC) transformation into 
osteoblast-like cells that can cause medial calcifications. 
Activin A receptor type I/activin-like kinase 2-activating 
mutations cause fibrodysplasia ossificans progressive 
(FOP), a genetic disorder leading to heterotopic ossifica-
tion. Recent data from Hruska et al [5] support the role 
of activin and its receptor as a cause of vascular disease 
in CKD. In VSMCs from nondiabetic/nonatherosclerotic 
aortas, CKD increases both ActRIIA signaling and vascu-
lar fibroblast signaling, thus causing osteogenic transi-
tion and stimulating vascular calcification [5]. ActRIIA 
signaling was activated by CKD throughout the body in 
a murine homologue of X-linked Alport syndrome [6]. 
In addition, an ActRIIA ligand trap was shown to reverse 
CKD-stimulated bone remodeling, likely through inhibi-
tion of activin-A induced osteoclastogenesis [7]. These 
observations in preclinical studies identify ActRIIA sig-
naling as a therapeutic target for CKD-MBD.
In a study of the association between serum MSTN lev-
els and abdominal aortic calcification (AAC) reported in 
this issue of Kidney Research and Clinical Practice, Lee et 
al [8] tested the hypothesis that MSTN is involved in the 
calcification of the vascular wall in patients with CKD. In 
a cross-sectional study, they evaluated AAC in the lateral 
lumbar spine using plain radiography and bone mineral 
density (BMD) in 71 maintenance hemodialysis patients. 
They classified patients into two groups according to the 
median value of MSTN. They observed that higher AAC 
scores are associated with low MSTN levels. In addition, 
circulating MSTN had a positive association with skel-
etal muscle mass and indexes of BMD measured at the 
total hip and femur neck. Their study, albeit limited by a 
relatively small number of subjects, is interesting since it 
identifies the activation of the ActR II receptor as a me-
diator of vascular damage in CKD.
The emergence of MSTN as a potentially modifiable risk 
factor in many catabolic conditions has led to growing 
interest in its measurement in serum as a tool to assess 
patient risk and target therapy. Muscle MSTN is robustly 
associated with wasting and muscle atrophy in patients 
with CKD, but the clinical utility of MSTN measurements 
in serum or blood is still unknown. The current hypoth-
esis regarding MSTN activation in serum suggests that 
the latent MSTN complex is secreted into circulation 
from muscle, and that the activity of this complex is regu-
lated by bone morphogenic protein-1 (BMP-1)/tolloid 
metalloproteinases and secreted inhibitors [1]. Although 
complete loss of MSTN expression can induce significant 
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Figure 1. Effects of activin A and myo-
statin in nonclassical tissues: vascu-
lar smooth muscle cells and bone. 
CKD, chronic kidney disease; MBD, min-
eral bone disorder. 
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muscle fiber hypertrophy, quantitative relationships be-
tween MSTN levels and the sizes of mature muscles have 
not been demonstrated. Muscle mass in mature mice 
increases in proportion to the extent of MSTN depletion 
below a certain threshold, but does not increase in mice 
with 40% decreases in MSTN expression. These data are 
also consistent with the lack of correlation between cir-
culating MSTN levels and lean body mass in normal hu-
man males [9]. The regulation of mature plasma MSTN 
production is also poorly known. After cleavage from the 
promyostatin, most of the mature MSTN is stored in a 
latent complex in the extracellular space [1], where it is 
bound to the propeptide that prevents it from binding to 
the receptor [1]. Activation of the latent complex releases 
the mature MSTN and allows it to interact with its recep-
tor. Several factors including low pH, free radicals, and 
proteases have been shown to activate the latent com-
plex [1]. However, the precise mechanisms that regulate 
MSTN release from its latent complex under physiologi-
cal and pathological conditions remain a matter for fur-
ther investigation.
Even less is known about patients with CKD. Plasma 
MSTN levels are elevated in early stages of CKD and in-
versely correlated with estimated glomerular filtration 
rate, suggesting that impaired renal removal and/or in-
creased MSTN production is responsible for increased 
levels [2]. Activin A plasma levels are also augmented in 
experimental uremia [5]. However, plasma follistatin-like 
3 (FSTL3), which counteracts activin/MSTN signaling, 
also increases during renal dysfunction [2]. On the con-
trary, FSTL levels are normally regulated in patients with 
advanced CKD, but their levels are correlated with in-
flammation and reduced muscle strength, suggesting the 
involvement of a mechanism that includes FSTL in the 
uremic wasting process [2]. In addition, in atherosclerotic 
lesions MSTN is largely expressed in CD45+ leucocytes 
infiltrating the vascular wall, suggesting that vascular, but 
not circulating MSTN, expresses atherosclerosis progres-
sion [3].
There are several caveats in the interpretation of the 
results obtained by Lee et al [8]. One is that the CKD 
subjects studied had circulating MSTN levels within 
the normal range. The biological meaning of variations 
in plasma MSTN within the physiological range, as ob-
served in this study, is not known. Lee et al [8] hypoth-
esize that lower MSTN levels reflect decreased muscle 
mass. As a matter of fact, in genetic diseases leading to 
muscle dystrophy (but not in healthy subjects), preserved 
muscle mass is associated with greater MSTN plasma lev-
els, since MSTN is produced within skeletal muscle [10]. 
Another puzzling issue is that in patients with CKD, there 
are several other circulating molecules that increase in 
the blood and may act on the activin II A/B receptor, such 
as activin A, GDF 11, and FSTL. In particular, plasma 
FSTL3, which counteracts activin/MSTN signaling, in-
creases in renal dysfunction, and its levels are correlated 
with inflammation and reduced muscle strength [11]. 
Clearly, obtaining measures of plasma MSTN and its cir-
culating inhibitors in blood could help assess the utility 
of measuring plasma MSTN as a biomarker of wasting.
In addition, there remain analytical and clinical chal-
lenges in translating MSTN serum testing into routine 
practice. Circulating MSTN levels have been measured 
by enzyme-linked immunosorbent assay (ELISA)-based 
assays directed at mature MSTN growth factor [12]. These 
assays, however, require acid dissociation of MSTN from 
the latent complex, with latent MSTN levels calculated 
based on differences between acid-treated and non-acid-
treated serum. Furthermore, the high amino acid similar-
ity of MSTN, activin A, and GDF11 raises the possibility 
of cross-reactivity in ELISA-based methods of detection. 
For these reasons, specific MSTN measurements have 
thus far been achieved only by mass spectrometry-based 
methods [13]. 
What is the meaning of the negative association be-
tween serum MSTN and AAC? Lee et al [8] suggest that 
higher MSTN is protective against vascular calcification. 
As an alternative explanation, the negative association 
between MSTN and AAC may be an effect of “reverse 
epidemiology,” a concept suggesting that nutritional and 
metabolic factors associated with worse outcomes in 
the general population also relate to outcomes in CKD 
patients, but in an opposite direction. This suggestion 
is fascinating, but it remains important to consider that 
previous studies in vascular smooth cell biology have 
shown that MSTN is primarily implicated in downregu-
lating cell cytoskeleton proteins, and therefore in hinder-
ing vascular remodeling, but not in mechanisms of vas-
cular calcification. On the contrary, activin A antagonism 
may protect against vascular calcifications. Therefore, 
the association observed may not be causal, and activin 
A levels (which were not studied by Lee et al [8]) could be 
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the link to the observed association.
The data shown by Lee et al [8], albeit preliminary in 
nature, lead to the hypothesis that acting on ActRIIA/B 
receptor signaling favorably modifies vascular calcifica-
tions. However, the results reported by Lee et al [8] are 
not sufficient to allow the extrapolation of MSTN mea-
surements into diagnostic strategies for patients with 
CKD. Given the negative correlation observed between 
MSTN levels and vascular calcifications and methodolog-
ic limitations, the hypothesis that MSTN protects against 
calcifications needs to be further tested. In addition, 
studies with larger sample sizes are required to evaluate 
relationships between circulating MSTN, systemic mark-
ers of inflammation, other metabolic parameters, and 
clinical outcomes, particularly cardiovascular outcomes, 
in patients with CKD. The tempting results demonstrated 
by Lee et al [8] are to be considered preliminary with re-
gard to unraveling the mechanisms leading to vascular 
damage in patients with CKD.
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